| 6/7/2022 |
Karkinos Healthcare partners with US-based C2i Genomics to expand AI cancer detection |
MobiHealthNews |
Photo by: Seksan Mongkhonkhamsao/Getty ImagesKarkinos Healthcare, a technology-driven cancer care platform in India, has entered into a strategic partnership with American oncology diagnostics firm C2i Genomics to promote AI-enabled cancer monitoring in the country.According to a press statement, their partnership will expand minimal residual disease (MRD) monitoring across Karkinos' network using C2i Genomics' whole-genome analysis platform. MRD refers to the small number of cancer ... |
| 6/5/2022 |
Biocept (NASDAQ:BIOC) Raised to Hold at Zacks Investment Research - Transcript Daily |
transcriptdaily.com |
Zacks Investment Research upgraded shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a sell rating to a hold rating in a report published on Thursday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ... |
| 6/5/2022 |
Biocept (NASDAQ:BIOC) Raised to Hold at Zacks Investment Research |
dispatchtribunal.com |
Zacks Investment Research upgraded shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a sell rating to a hold rating in a report published on Thursday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR ... |
| 6/4/2022 |
Biocept (NASDAQ:BIOC) Stock Rating Upgraded by Zacks Investment Research |
baseballnewssource.com |
Biocept ( NASDAQ:BIOC – Get Rating ) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The ... |
| 6/3/2022 |
Biocept (NASDAQ:BIOC) Stock Rating Upgraded by Zacks Investment Research |
defenseworld.net |
Biocept ( NASDAQ:BIOC – Get Rating ) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The ... |
| 6/3/2022 |
Biocept (NASDAQ:BIOC) Upgraded by Zacks Investment Research to “Hold” - Ticker Report |
Ticker Report |
Zacks Investment Research upgraded shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The ... |
| 6/1/2022 |
Medical Imaging Technologies for Oncology Diagnostics Market Size, Worldwide Opportunities, Driving Forces, Future Potential 2026 |
aeresearch.net |
This latest report studies Medical Imaging Technologies for Oncology Diagnostics market 2020 research report is replete with precise analysis from radical studies, specifically on queries that approach Market size, trends, share, forecast, outlook, production, and futuristic developments trends and present and future market status. The Medical Imaging Technologies for Oncology Diagnostics market report focuses on world major leading industry players with information like company profiles, product picture and specifications, Sales ... |
| 5/28/2022 |
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to “Sell” |
rivertonroll.com |
Zacks Investment Research cut shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE ... |
| 5/28/2022 |
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to “Sell” |
Daily Political |
... shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for ... |
| 5/28/2022 |
Biocept (NASDAQ:BIOC) Downgraded by Zacks Investment Research to “Sell” - Slater Sentinel |
slatersentinel.com |
Zacks Investment Research lowered shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a hold rating to a sell rating in a report released on Tuesday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE ... |
| 5/27/2022 |
Zacks Investment Research Lowers Biocept (NASDAQ:BIOC) to Sell - Stock Observer |
thestockobserver.com |
Zacks Investment Research lowered shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a hold rating to a sell rating in a report published on Tuesday morning, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE ... |
| 5/25/2022 |
Zacks Investment Research Downgrades Biocept (NASDAQ:BIOC) to Sell - Ticker Report |
Ticker Report |
lowered shares of Biocept ( NASDAQ:BIOC – Get Rating ) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test ... |
| 5/25/2022 |
Biocept (NASDAQ:BIOC) Rating Lowered to Sell at Zacks Investment Research |
etfdailynews.com |
Biocept ( NASDAQ:BIOC – Get Rating ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers ... |
| 5/25/2022 |
Biocept (NASDAQ:BIOC) Rating Lowered to Sell at Zacks Investment Research |
defenseworld.net |
Biocept ( NASDAQ:BIOC – Get Rating ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The ... |
| 5/24/2022 |
Biocept (NASDAQ:BIOC) Rating Lowered to Sell at Zacks Investment Research - The Cerbat Gem |
thecerbatgem.com |
Biocept ( NASDAQ:BIOC – Get Rating ) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, Zacks.com reports.According to Zacks, “Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers ... |
| 5/2/2022 |
North America Precision Medicine size to surpass |
Globe Newswire |
... industry outlook is seeing a positive turn. Earlier in 2020, the U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a novel drug for treating metastatic gastrointestinal stromal tumor or GIST. Two new oncology diagnostics , FoundationOne Liquid CDx test and Guardant360 CDx assay marked a step forward in precision oncology.Access sample pages of the report, “North America Precision Medicine Market Forecasts 2027” in detail along with the ... |
| 5/2/2022 |
North America Precision Medicine Market size to surpass |
Globe Newswire |
... industry outlook is seeing a positive turn. Earlier in 2020, the U.S. Food and Drug Administration (FDA) granted approval to avapritinib, a novel drug for treating metastatic gastrointestinal stromal tumor or GIST. Two new oncology diagnostics , FoundationOne Liquid CDx test and Guardant360 CDx assay marked a step forward in precision oncology.Access sample pages of the report, “North America Precision Medicine Market Forecasts 2027” in detail along with the ... |
| 4/26/2022 |
ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy |
Yahoo News |
... continue to expand our pipeline and proprietary data science tools," said Rosana Kapeller, M.D., Ph.D., President, Chief Executive Officer and Co-founder of ROME. "As a scientist by training who has deep experience in oncology diagnostics and therapeutics, Nurjana will play a key role in helping ROME bring a new class of medicines to patients."During Dr. Bachman’s tenure at Foundation Medicine, she built and led the team responsible ... |
| 4/26/2022 |
ROME Therapeutics Appoints Nurjana Bachman, Ph.D., as Senior Vice President, Corporate Development and Strategy |
Business Wire |
... to expand our pipeline and proprietary data science tools,” said Rosana Kapeller, M.D., Ph.D., President, Chief Executive Officer and Co-founder of ROME. “As a scientist by training who has deep experience in oncology diagnostics and therapeutics, Nurjana will play a key role in helping ROME bring a new class of medicines to patients.”During Dr. Bachman’s tenure at Foundation Medicine, she built and led the team ... |
| 3/31/2022 |
2022 Worldwide Medical Devices Report - Increasing Healthcare Expenditures and Growth of Emerging Economies Have Increased the Demand for Technologically Superior Medical Devices |
PR Newswire |
... of medical devices market should reach $108.6 billion by 2025 from $68.0 billion in 2020 at a compound annual growth rate (CAGR) of 9.8% for the forecast period of 2020 to 2025.The global oncology diagnostics market should reach $128.3 billion by 2025 from $86.7 billion in 2020 at a compound annual growth rate (CAGR) of 8.1% for the forecast period of 2020 to 2025.The global dermatology devices market ... |